Compare Aurobindo Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TORRENT PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA TORRENT PHARMA AUROBINDO PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 18.1 38.5 47.0% View Chart
P/BV x 3.9 9.8 40.2% View Chart
Dividend Yield % 0.3 0.6 43.1%  

Financials

 AUROBINDO PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
TORRENT PHARMA
Mar-19
AUROBINDO PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs8301,964 42.3%   
Low Rs5271,245 42.3%   
Sales per share (Unadj.) Rs333.9453.4 73.6%  
Earnings per share (Unadj.) Rs40.425.8 156.5%  
Cash flow per share (Unadj.) Rs51.862.3 83.1%  
Dividends per share (Unadj.) Rs2.5017.00 14.7%  
Dividend yield (eoy) %0.41.1 34.8%  
Book value per share (Unadj.) Rs237.1279.2 84.9%  
Shares outstanding (eoy) m585.91169.22 346.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.03.5 57.4%   
Avg P/E ratio x16.862.2 27.0%  
P/CF ratio (eoy) x13.125.8 50.9%  
Price / Book Value ratio x2.95.7 49.8%  
Dividend payout %6.265.9 9.4%   
Avg Mkt Cap Rs m397,569271,513 146.4%   
No. of employees `00017.913.6 131.3%   
Total wages/salary Rs m25,84914,038 184.1%   
Avg. sales/employee Rs Th10,956.95,642.6 194.2%   
Avg. wages/employee Rs Th1,447.71,032.4 140.2%   
Avg. net profit/employee Rs Th1,324.3320.9 412.7%   
INCOME DATA
Net Sales Rs m195,63676,728 255.0%  
Other income Rs m1,553571 272.3%   
Total revenues Rs m197,18977,299 255.1%   
Gross profit Rs m39,51919,831 199.3%  
Depreciation Rs m6,6806,177 108.1%   
Interest Rs m2,6265,038 52.1%   
Profit before tax Rs m31,7679,187 345.8%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-3,570 24.7%   
Tax Rs m7,2691,254 579.9%   
Profit after tax Rs m23,6454,363 541.9%  
Gross profit margin %20.225.8 78.2%  
Effective tax rate %22.913.6 167.7%   
Net profit margin %12.15.7 212.5%  
BALANCE SHEET DATA
Current assets Rs m153,64550,375 305.0%   
Current liabilities Rs m120,42951,653 233.1%   
Net working cap to sales %17.0-1.7 -1,019.5%  
Current ratio x1.31.0 130.8%  
Inventory Days Days13592 146.8%  
Debtors Days Days6468 93.3%  
Net fixed assets Rs m103,90983,648 124.2%   
Share capital Rs m586846 69.2%   
"Free" reserves Rs m138,32246,397 298.1%   
Net worth Rs m138,90847,244 294.0%   
Long term debt Rs m1,80039,129 4.6%   
Total assets Rs m264,544141,209 187.3%  
Interest coverage x13.12.8 463.8%   
Debt to equity ratio x00.8 1.6%  
Sales to assets ratio x0.70.5 136.1%   
Return on assets %9.96.7 149.2%  
Return on equity %17.09.2 184.3%  
Return on capital %23.812.3 193.2%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31622,103 440.3%   
Fx outflow Rs m40,5895,522 735.1%   
Net fx Rs m56,72716,581 342.1%   
CASH FLOW
From Operations Rs m16,22017,981 90.2%  
From Investments Rs m-28,768-2,413 1,192.3%  
From Financial Activity Rs m19,191-13,145 -146.0%  
Net Cashflow Rs m6,6562,380 279.7%  

Share Holding

Indian Promoters % 54.1 71.5 75.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 7.0 113.2%  
FIIs % 27.7 12.6 219.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.8 115.9%  
Shareholders   69,601 26,511 262.5%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends at Record High; Tata Motors and Adani Ports Among Top Nifty Gainers(Closing)

Indian share markets extended gains to the second day today and ended at record-high levels with Nifty ending above 14,600-mark.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 20, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - WYETH COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS